Scarica l'app Stockscreener
198.99
1.86%
-3.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Resmed Inc Borsa (RMD) Ultime notizie
ResMed stock trades steady as sleep apnea demand supports earnings - ad-hoc-news.de
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276 - Moomoo
Resmed to sell MatrixCare business to PE firm Frazier Healthcare Partners - DOTmed
ResMed stock stabilizes as investors weigh recent growth and margin trends - ad-hoc-news.de
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed downgraded at RBC Capital Markets on FY27 challenges - MSN
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
FDA issues early alert for certain Resmed Astral ventilators - MassDevice
How much could ResMed shares rise according to Morgans? - The Motley Fool Australia
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating - Moomoo
ResMed shares rise over 3% as $490 million MatrixCare divestment fuels buybacks - Traders Union
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
Why Is ResMed Stock Down Today? - Kalkine
Health Check: Restless investors question sleep giant Resmed’s short-term prospects - Stockhead
ResMed (ASX:RMD) Falls — What Is Behind the Medical Device Giant’s Session Decline? - Kalkine
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset? - Kalkine Media
ResMed Price Target Cut 1.8% to A$40.97/Share by Morgans - Moomoo
Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges - TradingView
Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges - PR Newswire
Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34 - Moomoo
Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270 - Moomoo
ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup - Moomoo
ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews
ResMed stock reflects steady demand for sleep apnea solutions - ad-hoc-news.de
Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 - marketscreener.com
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed Stock Sinks as Citi Sounds Supply Alarm - TipRanks
ResMed Inc. stock falls Wednesday, underperforms market - MSN
In an era of ‘baddies,’ companies are racing to keep up with the influencer economy - CNN
How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - Sahm
ResMed (RMD) Divestiture of MatrixCare presentation Summary - Quartr
ResMed Is Maintained at Hold by Jefferies - Moomoo
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - Yahoo Finance
Jefferies Adjusts Price Target on ResMed to $225 From $240 - marketscreener.com
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health - Yahoo Finance
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Ord Minnett - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie - The Globe and Mail
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact - simplywall.st
ResMed Analyst Backs Portfolio Reset - Benzinga
ResMed's Q4 2026 Earnings: What to Expect - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and ResMed - Yahoo Finance
What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares? - Kalkine
Form 4 ResMed Inc For: 9 July By Investing.com - Investing.com Nigeria
ResMed chairman & CEO Michael Farrell sells $1.09m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing - marketscreener.com
ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan - Stock Titan
ResMed Inc. highlights sleep and respiratory focus as investors track Nasdaq-listed shares - Ad-hoc-news.de
ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says - marketscreener.com
ResMed to sell MatrixCare business to Frazier Healthcare Partners - MSN
ResMed's billion-dollar blowup - intelligentinvestor.com.au
ResMed's $490M Sale Looks Strategically Sound -- Market Talk - Moomoo
ResMed Willing to Cut Underperforming Assets -- Market Talk - Moomoo
1.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):